Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€106.10

€106.10

-0.360%
-0.38
-0.360%
€127.54
 
18:00 / Tradegate WKN: 850103 / Symbol: ABT / Name: Abbott / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Abbott Laboratories Stock

The price for the Abbott Laboratories stock decreased slightly today. Compared to yesterday there is a change of -€0.380 (-0.360%).
With 38 Buy predictions and not a single Sell prediction Abbott Laboratories is an absolute favorite of our community.
As a result the target price of 127 € shows a slightly positive potential of 19.7% compared to the current price of 106.1 € for Abbott Laboratories.
Criterium "Brand" is seen as the biggest plus for Abbott Laboratories stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Abbott Laboratories in the next few years

Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Abbott Laboratories vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Abbott Laboratories -0.360% -5.903% -7.841% 13.506% -2.669% -1.771% 24.991%
Elanco Animal Health Inc. 0.000% -1.662% 7.212% 7.433% 8.642% -37.830% -38.919%
Johnson & Johnson 0.460% 4.580% 8.167% -1.097% 1.136% -16.154% 8.250%
Pfizer Inc. 1.690% -4.419% -0.216% -24.601% -18.151% -58.553% -31.391%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-01

Examining the financials of the pharmaceutical giant Abbott Laboratories, with its ticker symbol ABT, one can't help but form an initial impression tinged with intrigue. Abbott stands as a prominent entity in the healthcare sector, known for its diversified portfolio ranging from medical devices to nutritional products and branded generic medications. This diversity is reflected in its robust financial statements, showcasing the company's significant market presence and operational efficiency.

The sheer magnitude of Abbott's total assets, which hovered consistently above the $70 billion mark from 2020 to 2022, signals a company with considerable resources and a solid financial foundation. Across the same period, the evolution of its balance sheet reveals a healthy balance between liabilities and stockholder equity, pointing to sound financial management. The company's liquidity, as illustrated by its cash reserves, provides confidence in Abbott's ability to meet short-term obligations and invest in growth opportunities.

Profitability and Revenue Streams Abbott has demonstrated an admirable profit margin and a stable operating margin, hinting at its efficiency in converting revenue into profit and managing its operational expenses. The company's net income has shown relative growth, especially when evaluating the year-over-year rise from 2020 to 2022, indicating a consistent upward trajectory in profitability.

Comments

Abbott Laboratories (NYSE: ABT) was upgraded by analysts at William Blair to a "strong-buy" rating.
Ratings data for ABT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -0.49%
Target price 122.148
Change
Ends at 18.07.26

Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Wells Fargo & Company from $147.00 to $142.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -1.17%
Target price 121.288
Change
Ends at 18.07.26

Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Raymond James Financial, Inc. from $142.00 to $141.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Show more

News

Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield: https://www.marketbeat.com/logos/articles/med_20250717083934_chart-abt-7172025.png
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock

Abbott Reports 10.5% EPS Growth for Fiscal Q2
Abbott Reports 10.5% EPS Growth for Fiscal Q2

Abbott Laboratories (NYSE:ABT), a global healthcare company known for its medical devices, diagnostics, nutrition, and pharmaceuticals, reported fiscal 2025 earnings on Thursday, July 17, that

Abbott (ABT) Q2 2025 Earnings Call Transcript
Abbott (ABT) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool.

Need a quote from one of our analysts? Email [email protected]

Abbott Laboratories (NYSE:ABT) presented a quarter marked by distinct segment divergence, with medical devices